Cat. No.: HY-U00434

3BDO

21 Cited Publications

Avis client

Based on 21 publication(s) in Google Scholar

3BDO is a IFITM3 modulator and mTOR activator with antiviral and autophagy-inhibiting effects. 3BDO exhibits inhibitory activity against porcine coronaviruses. 3BDO increases the protein abundance of IFITM3, inhibits virus-cell membrane fusion, and blocks viral entry. 3BDO inhibits the entry of transmissible gastroenteritis virus, porcine epidemic diarrhea virus, and porcine respiratory coronavirus into host cells. 3BDO can be used for research on porcine coronavirus infection.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.93%
CAS No.: 890405-51-3
Formule: C₁₈H₁₇NO₅
Masse moléculaire:327.33

Stockage:

Pure form -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

3BDO Chemical Structure

CAS No.: 890405-51-3

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (21)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

IC₅₀ & Target

mTOR

Voir tous les produits spécifiques à Isoform mTOR :

In Vitro

3BDO (20 μM; 19 h) potently inhibits TGEV infection in porcine intestinal organoid monolayers with an IC₅₀ of 14.6 μM and a high selectivity index of 87.67, indicating an acceptable safety margin^[1].
3BDO (15-60 μM; 18 h) inhibits TGEV infection in porcine intestinal organoid monolayers in vitro in a dose-dependent manner, reducing viral protein levels, viral titers, and viral fluorescence signal^[1].
3BDO (60 μM) restricts TGEV infection in ST cells and porcine intestinal organoid monolayers by specifically targeting viral entry, with no effect on viral inactivation, attachment, replication, or release^[1].
3BDO blocks TGEV entry in ST cells by specifically enhancing IFITM3 protein abundance, as knockdown of IFITM3 eliminates its antiviral activity^[1].
3BDO blocks PRCV entry in ST cells and PEDV entry in PK-15 cells by enhancing IFITM3 protein abundance, as knockdown of IFITM3 eliminates its antiviral activity against both viruses^[1].
In an autophagy induction model, 3BDO inhibits the Rapamycin (HY-10219)-induced increase in the number of MAP1LC3B puncta, the elevation of MAP1LC3B-II levels, and the reduction of SQSTM1 protein levels^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

In the atherosclerosis model of apoE^-/- mice, 3BDO inhibits endothelial autophagy and apoptosis, prevents endothelial injury, and stabilizes established atherosclerotic lesions^[3].
3BDO significantly reduces serum IL-6 and IL-8 levels in apoE^-/- mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 890405-51-3
Appearance Solid-Liquid Mixture
Masse moléculaire 327.33
Formule C₁₈H₁₇NO₅
Color Off-white to light yellow
SMILES

O=C1OC(COC2=C([N+]([O-])=O)C=CC=C2)CC1CC3=CC=CC=C3
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Pure form	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (21)

All Cell Proliferation/Viability AssayWB

Sort by:

Journal Impact Factor

Nat Commun

Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma. [Abstract]

2024 Aug 9;15(1):6810. PMID: 39122682

3BDO purchased from MedChemExpress. Usage Cited in: Nat Commun. 2024 Aug 9;15(1):6810. [Abstract]

Effect on cell viability of NCI-H929 cells infected with scramble or PPP1R15B-targeting shRNAs after treatment with the mTOR activator 3BDO (20 µM) for 48 hours.
Cell Death Differ

AF9 targets acetyl-modified STAT6 to diminish purine metabolism and accelerate cell apoptosis during metastasis. [Abstract]

2023 Jul;30(7):1695-1709. PMID: 37308587
EBioMedicine

F. nucleatum facilitates oral squamous cell carcinoma progression via GLUT1-driven lactate production. [Abstract]

2023 Feb:88:104444. PMID: 36709580
Cancer Lett

Platelets promote primary hepatocellular carcinoma metastasis through TGF-β1-mediated cancer cell autophagy. [Abstract]

2024 Aug 6:217161. PMID: 39117067
Acta Biomater

Graphene oxide induces p62/SQSTM-dependent apoptosis through the impairment of autophagic flux and lysosomal dysfunction in PC12 cells. [Abstract]

2018 Nov:81:278-292. PMID: 30273743

3BDO purchased from MedChemExpress. Usage Cited in: Acta Biomater. 2018 Nov:81:278-292. [Abstract]

PC12 cells are pretreated with 740-YP (30 μM), or SC79 (13.7 μM), or 3BDO (100 μM) for 1 h, and for the duration of GO (50 μg/mL) incubation for 24 h. LC3 turnover is detected by western blotting.
J Transl Med

HMGCL activates autophagy in osteosarcoma through β-HB mediated inhibition of the PI3K/AKT/mTOR signaling pathway. [Abstract]

2025 Feb 21;23(1):219. PMID: 39985081
Appl Mater Today

2021, 101066.
Int J Mol Med

Autophagy inhibition enhances the inhibitory effects of ursolic acid on lung cancer cells. [Abstract]

2020 Nov;46(5):1816-1826. PMID: 32901853
Biochem Pharmacol

Ginsenoside Rh4 suppresses aerobic glycolysis and the expression of PD-L1 via targeting AKT in esophageal cancer. [Abstract]

2020 Aug;178:114038. PMID: 32422139
J Ethnopharmacol

Licochalcone A promotes autophagy to ameliorate NAFLD by inhibiting the mTOR and regulating ULK1/Beclin1/VPS34 pathway. [Abstract]

2025 Jul 29:120333. PMID: 40744422
J Ethnopharmacol

Xiao-Er-Kang-Du capsules regulate autophagy against the influenza B virus (Victoria strain) through the mTOR/ULK1/Beclin1/VPS34 pathway. [Abstract]

2025 Jan 30;337(Pt 2):118872. PMID: 39366496
Respir Res

Combination of betulinic acid and EGFR-TKIs exerts synergistic anti-tumor effects against wild-type EGFR NSCLC by inducing autophagy-related cell death via EGFR signaling pathway. [Abstract]

2024 May 20;25(1):215. PMID: 38764025
Front Pharmacol

CC-223, NSC781406, and BGT226 Exerts a Cytotoxic Effect Against Pancreatic Cancer Cells via mTOR Signaling. [Abstract]

2020 Nov 11;11:580407. PMID: 33343350
Aging (Albany NY)

Gastrodin ameliorates learning and memory impairment in rats with vascular dementia by promoting autophagy flux via inhibition of the Ca2+/CaMKII signal pathway. [Abstract]

2021 Mar 10;13(7):9542-9565. PMID: 33714957
J Virol

Potassium molybdate blocks APN-dependent coronavirus entry by degrading receptor via PIK3C3-mediated autophagy. [Abstract]

2024 Dec 6:e0144924. PMID: 39641621
Neurochem Res

3BDO Alleviates Seizures and Improves Cognitive Function by Regulating Autophagy in Pentylenetetrazol (PTZ)-Kindled Epileptic Mice Model. [Abstract]

2022 Dec;47(12):3777-3791. PMID: 36243819
Am J Physiol Gastrointest Liver Physiol

Revitalizing gut barrier integrity: miR-192-5p's role in enhancing autophagy via Rictor in enteritis. [Abstract]

2024 Sep 1;327(3):G317-G332. PMID: 38954822
Vet Microbiol

The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]

2026 May:316:110992. PMID: 41865607
Vet Microbiol

Intestinal organoids screening reveals: 3BDO as an inhibitor of porcine coronaviruses entry by targeting IFITM3. [Abstract]

2026 Jan 27:315:110907. PMID: 41712999
Arch Physiol Biochem

Mangiferin prevents glucolipotoxicity-induced pancreatic beta-cell injury through modulation of autophagy via AMPK-mTOR signaling pathway. [Abstract]

2024 Sep 3:1-10. PMID: 39225043
University of Liege

2024.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (305.50 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 20 mg/mL (61.10 mM; Need ultrasonic)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.0550 mL

15.2751 mL

30.5502 mL

5 mM

0.6110 mL

3.0550 mL

6.1100 mL

10 mM

0.3055 mL

1.5275 mL

3.0550 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (7.64 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Kinase Assay^[1]

Total protein is obtained from HUVECs by using of IP lysis buffer after treatment with rapamycin (10 μM), 3BDO (60 μM) or both for 6 h. After centrifuging at 4°C, the supernatant is collected and incubated with protein A/G agarose beads and TIA1 antibody or normal mouse IgG as a control at 4°C overnight. The beads are washed 3 times with IP lysis buffer and then eluted with 4×SDS loading buffer. Ser phosphorylation is detected by western blot assay with Ser phosphorylation antibody^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Assay^[1]

HUVECs are isolated from umbilical cords and cultured in M199 medium with 20% (v/v) fetal bovine serum and 10 IU/mL fibroblast growth factor 2 (FGF2) in a humidified incubator at 37°C with 5% CO₂. Cells up to passage 10 are used for experiments. When HUVECs are grown to 80% confluency, HUVECs are treated with DMSO or 60 µM 3BDO for 24 h, then total RNA is extracted^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[2]

Male apoE^-/- mice (8 weeks old) are used in this study. ApoE^-/- mice are fed an atherogenic diet (containing 21% fat and 0.15% cholesterol). To avoid the potential confounding effects of variation among batches of diet, a single batch is reserved and used throughout the experiment. Mice at 20 weeks older are divided into 3 groups for treatment (n=8 mice/group) for 8 weeks: control (DMSO), low-dose 3BDO (50 mg/kg/d; 3BDO-L) and high-dose 3BDO (100 mg/kg/d; 3BDO-H). The body weight of mice is measured every week during 3BDO injection. Blood samples are taken from the inferior vena cava, and animals are killed by exsanguination^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Zhang Y, et al. Intestinal organoids screening reveals: 3BDO as an inhibitor of porcine coronaviruses entry by targeting IFITM3[J]. Veterinary Microbiology, 2026: 110907.

[2]. Ge D, et al. Identification of a novel MTOR activator and discovery of a competing endogenous RNA regulating autophagy in vascular endothelial cells. Autophagy. 2014 Jun;10(6):957-71. [Content Brief]

[3]. Peng N, et al. An activator of mTOR inhibits oxLDL-induced autophagy and apoptosis in vascular endothelial cells and restricts atherosclerosis in apolipoprotein E-/- mice. Sci Rep. 2014 Jul 1;4:5519. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
Ethanol / DMSO	1 mM	3.0550 mL	15.2751 mL	30.5502 mL	76.3755 mL
	5 mM	0.6110 mL	3.0550 mL	6.1100 mL	15.2751 mL
	10 mM	0.3055 mL	1.5275 mL	3.0550 mL	7.6376 mL
	15 mM	0.2037 mL	1.0183 mL	2.0367 mL	5.0917 mL
	20 mM	0.1528 mL	0.7638 mL	1.5275 mL	3.8188 mL
	25 mM	0.1222 mL	0.6110 mL	1.2220 mL	3.0550 mL
	30 mM	0.1018 mL	0.5092 mL	1.0183 mL	2.5459 mL
	40 mM	0.0764 mL	0.3819 mL	0.7638 mL	1.9094 mL
	50 mM	0.0611 mL	0.3055 mL	0.6110 mL	1.5275 mL
	60 mM	0.0509 mL	0.2546 mL	0.5092 mL	1.2729 mL
DMSO	80 mM	0.0382 mL	0.1909 mL	0.3819 mL	0.9547 mL
DMSO	100 mM	0.0306 mL	0.1528 mL	0.3055 mL	0.7638 mL

Keywords

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

3BDO

Anti-Infection Compound Library

Apoptosis Compound Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Antiviral Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Oxygen Sensing Compound Library

Anti-Cardiovascular Disease Compound Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Antidepressant Compound Library

Heterocyclic Compound Library

Pain-Related Compound Library

Cell Death Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Anti-Brain Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) 3BDO

Voir tous les produits spécifiques à Isoform mTOR

Activité biologique

Chemical Information

Publications (21)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

3BDO Related Classifications

HY-U00434 Related Classifications